Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04336241
Title Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Replimune Inc.

esophageal cancer

gastrointestinal system cancer

gastroesophageal junction adenocarcinoma

hepatocellular carcinoma

lung cancer

breast cancer

Advanced Solid Tumor

uveal melanoma

colorectal cancer

stomach cancer


Nivolumab + RP2


Age Groups: adult | senior
Covered Countries ESP

No variant requirements are available.